N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts

M. L. Rinne, Y. He, B. F. Pachkowski, J. Nakamura and M. R. Kelley

1Department of Biochemistry and Molecular Biology and 2Department of Pediatrics, Herman B. Wells Center for Pediatric Research and 3Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA and 4Department of Environmental Sciences and Engineering, School of Public Health, University of North Carolina, Chapel Hill, NC 27599, USA

Received March 17, 2005; Revised and Accepted April 29, 2005

ABSTRACT

Previous studies indicate that overexpression of N-methylpurine DNA glycosylase (MPG) dramatically sensitizes cells to alkylating agent-induced cytotoxicity. We recently demonstrated that this sensitivity is preceded by an increased production of AP sites and strand breaks, confirming that overexpression of MPG disrupts normal base excision repair and causes cell death through overproduction of toxic repair intermediates. Here we establish through site-directed mutagenesis that MPG-induced sensitivity to alkylation is dependent on enzyme glycosylase activity. However, in contrast to the sensitivity seen to heterogeneous alkylating agents, MPG overexpression generates no cellular sensitivity to MeOSO2(CH2)2-lexitropsin, an alkylator which exclusively induces 3-meA lesions. Indeed, MPG overexpression has been shown to increase the toxicity of alkylating agents that produce 7-meG adducts, and here we demonstrate that MPG-overexpressing cells have dramatically increased removal of 7-meG from their DNA. These data suggest that the mechanism of MPG-induced cytotoxicity involves the conversion of non-toxic 7-meG lesions into highly toxic repair intermediates. This study establishes a mechanism by which a benign DNA modification can be made toxic through the overexpression of an otherwise well-tolerated gene product, and the application of this principle could lead to improved chemotherapeutic strategies that reduce the peripheral toxicity of alkylating agents.

INTRODUCTION

Many cancer chemotherapeutics achieve their medicinal effects by producing DNA lesions that trigger the interruption of cell division and ultimately lead to cell death. However, because chemotherapy does not exclusively target tumor cells, the adverse effects on normal tissues limit the doses that can be administered to patients (1). Because peripheral side effects limit treatment, tumor cells are often inadequately eliminated and the outgrowth of drug resistant clones is allowed. In order to advance cancer treatment toward a cure, chemotherapy needs to be made both more specific and more effective.

Chemotherapeutic drugs frequently modify DNA through oxidation and alkylation reactions (2), producing DNA adducts that are identified and replaced by the base excision repair (BER) pathway (3). BER involves the recognition and removal of damaged bases by a DNA glycosylase, followed by incision of the resulting abasic (AP) site by AP endonuclease (Ape 1), DNA synthesis by polymerase and strand ligation by DNA ligase (4). This pathway, therefore, involves the processing of modest structural DNA damage through toxic baseless and strand-interrupted species (5–7), which may transiently replace less toxic or non-toxic DNA lesions in the course of restoring the DNA sequence.

We have been interested in intervening into the BER pathway to improve the efficacy of cancer chemotherapy. Recent studies show that transient overexpression of N-methylpurine DNA glycosylase (MPG) increases the cytotoxicity of alkylating agents such as temozolomide in breast cancer cells (8). Cells that overexpress MPG also have higher numbers of alkylating agent-induced AP sites and/or single-stranded DNA breaks as well as double-stranded DNA breaks, which are the likely cause of this increased toxicity. These data suggest that overexpression of MPG creates an ‘imbalance’ in the BER pathway which leads to saturation of downstream...
repair enzymes and accumulation of toxic intermediates (8,9).
Implicit is the idea that the intermediates produced are more
detrimental to the cell that the alkylated base lesions from
which they originate. Having established the accumulation of
toxic BER intermediates, we turned our attention toward
identifying the products of alkylation that lead to MPG
overexpression-induced sensitivity.

The major site of alkylation for all methylating agents is the
highly nucleophilic N7 nitrogen of guanine. N7-methylguanine
(7-meG) makes up 70–90% of the adducts produced by
methylation, with fewer modifications occurring at the
N3 position of adenine (3-meA) and fewest at the O6 position
of guanine (O6-meG). Though quantitatively the most signifi-
cant of these principal lesions, 7-meG has little, if any, effect
on the cell. DNA duplex structure is unaltered by the addition
of this methyl group, and 7-meG has the same coding prop-
erties as unmodified guanine. In fact, 7-meG is neither muta-
genic nor toxic and appears to be in all ways harmless, as it is
tolerated by the cell for generations. In contrast, the minor
lesions 3-meA and O6-meG are primarily responsible for the
cellular effects of methylation: 3-meA inhibits DNA poly-
merase and arrests DNA synthesis, leading to sister chromatid
exchange, chromosome breaks and cell death; O6-meG is
highly mutagenic and may, under certain circumstances,
block DNA replication.

MPG recognizes and removes 3-meA and 7-meG (10), the
most common methylated DNA lesions (11). Increased
alkylation-induced cytotoxicity in MPG-overexpressing cells
probably reflects an increased load of intermediates produced
by incomplete repair of 3-meA adducts, 7-meG adducts or
both. We decided to investigate the mechanism of MPG-
induced alkylation sensitivity, with particular attention on
the inciting lesions.

Here we demonstrate, through the use of inactive site-
directed mutants, that MPG-driven alkylation sensitivity is
dependent on the enzyme’s glycosylase activity. We addi-
tionally found that, although MPG overexpression causes sensi-
tivity to classic monofunctional alkylating agents, it imparts
no sensitivity to the 3-meA specific agent MeOSO2(CH2)2-
lexitropsin (Me-lex), arguing against a role for 3-meA removal
in generating alkylating agent sensitivity. Specific adduct
analysis revealed that MPG overexpression causes rapid,
expert-to-total removal of 7-meG from the DNA. This strongly
implies the conversion of non-toxic 7-meG adducts to
toxic repair intermediates in explaining MPG-induced alkyla-
tion sensitivity. The exchange of harmless base changes for
toxic genetic interruptions represents a novel approach to
cancer treatment that could decrease side effects and increase
the likelihood of a cure.

MATERIALS AND METHODS

Cell lines and culture conditions

The human mammary gland adenocarcinoma cell line
MDA-MB231 was purchased at passage number 29 from
the American Type Culture Collection (ATCC, Manassas,
VA, USA). Cells were grown at 37°C in a 5% CO₂
water-humidified chamber (Forma Scientific, Marietta, OH, USA),
and cultured in RPMI 1640 media (Invitrogen Corporation,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (Hyclone Laboratories, Logan, UT, USA). A 1% penicillin/streptomycin antimicrobial solution (Invitrogen)
was included in stable stock culture but not in experimental
cultures, and cells were replaced by fresh frozen stocks before
25 passages in our lab.

Site-directed mutagenesis

Two inactive site-directed mutants of HA-MPG were con-
structed using a QuickChange Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA, USA), according to the manu-
facturer’s protocol. An alanine was substituted for glutamic acid residue 125 (E125A), using a mutagenic primer (5′-
CGCATCGTGGAGACCGCGCATAACCTGGGCCC-3′)
and its complement, both containing a point mutation (under-
lined) that would change the glutamic acid codon to an alanine
(bold). An additional MPG mutant was generated by substi-
tuting tyrosine 162 with alanine, using the following primer and
its complement: 5′- CCTGTA CGTGACATCATTTGC-C
CGCATGTACTTCG-3′ (mutation underlined; codon
change in bold). These two mutants have minimal glycosylase
activity (12). Glu-125 deprotonates a bound water molecule
that is required for glycosylic bond cleavage. However, the
E125A mutation eliminates glycosylase activity. Tyr-162
intercalates into the minor groove, flipping a damaged nucle-
otide into the enzyme’s active site, where cleavage can occur.
Y162A mutants have minimal glycosylase activity. Site-
directed mutagenesis with these mutagenic primers was
performed on HA-MPG in the pCR2.1 vector, and the result-
ning constructs were sequenced to verify that the desired
mutations had been introduced into the HA-MPG sequence.
Both mutants were then moved into the modified adenoviral
shuttle vector pacAd5 IRES EGFP, using BamHI and Xhol
restriction sites.

Adenoviral infection

The HA-MPG-, HA-E125A- and HA-Y162A-containing
adenoviral shuttle vectors and empty vector control (pacAd5
IRES2EGFP) were sent to the University of Iowa Gene
Transfer Vector Core Laboratory for production and titering
of replication-defective recombinant adenovirus (13). Adeno-
virus stocks (Ad5 IRES2EGFP, Ad5 E125A, Ad5 Y162A
and Ad5 HA-MPG) were aliquoted and stored at –80°C until
the time of infection. Adenoviral infection was performed as pre-
viously reported (8), using MDA-MB231 breast cancer cells at
60–90% confluence that were washed with phosphate-buffered
saline (PBS), trypsinized for 10–15 min and resuspended in
a known volume of medium. Identical cell numbers ranging
from 5 × 10⁶ to 6 × 10⁶ cells were pelleted and resuspended
in 50 µl of PBS and purified adenovirus at a multiplicity of
infection of 15 IU/cell. Infections were carried out for 3 h
at 37°C in a 5% CO₂ water-humidified chamber with gentle
agitation every 20–30 min. Infected cells were resuspended
in 10 ml 10% RPMI, mixed thoroughly and plated for cell
survival assays. Infection efficiencies of transduced cells were
determined 24 h after infection by measuring EGFP fluores-
cence intensities of 10⁵ cells using a FACSCalibur fluores-
cence activated cell sorter (Becton-Dickinson, San Jose, CA,
USA). Results were analyzed with Cell-Quest 3.3 software
(Becton-Dickinson). EGFP expression levels were also visu-
alized by fluorescence microscopy using a Nikon TS-100F
Western blot analysis
Western blots were performed according to the Invitrogen NuPage protocol (Invitrogen) as outlined previously (8). Briefly, 20 μg protein was analyzed on a 10% Bis-Tris NuPAGE gel and transferred to a nitrocellulose (NC) membrane. Membranes were probed using monoclonal MPG antibody (kindly provided by Dr Rabindra Roy, University of Texas Medical Branch, Galveston, TX, USA), followed by horseradish peroxidase-conjugated rabbit anti-mouse 
IgG (Chemicon International, Temecula, CA, USA). Antibody binding was detected using chemiluminescence (Roche Diagnostics Corp., Indianapolis, IN, USA), and equal loading was confirmed by probing with pan Actin monoclonal Ab (NeoMarkers Inc., Fremont, CA, USA).

DNA isolation
DNA was isolated from cultured cells using the PureGene DNA extraction kit (Gentra Systems Inc., Minneapolis, MN, USA). Briefly, cell pellets were thawed and lysed in lysis buffer supplemented with 20 mM 2,2,6,6-tetramethyl-piperidinoxyl (TEMPO; Aldrich). Protein was precipitated by centrifugation. The DNA pellet was resuspended in sterilized distilled water with 2 mM TEMPO, and DNA samples were stored at −80°C until analysis.

Drug treatment
Infected cells were treated with DNA-damaging agents 24 h after adenoviral exposure (8). Infected cells were treated with Me-lex (a kind gift from Dr Barry Gold, University of Nebraska, Omaha, NE, USA), temozolomide (a kind gift from Dr Robert Bishop, Schering Corp., Kenilworth, NJ, USA), methylmethane sulfonate (MMS), ethyl nitrosourea (ENU), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), mitomycin C (MMC), Etoposide (all from Sigma Chemical Co., St Louis, MO, USA), thiotopea (Immuno Corp., Seattle, WA, USA) or cisplatin (Bristol Myers Squibb Co., Princeton, NJ, USA) for 1 h at 37°C in 5% CO2. Drug-containing media was removed and replaced with fresh growth medium, and cells were incubated for 24–48 h.

Cell survival assay
Survival of HA-MPG-overexpressing cells was measured 24 and 48 h after drug treatment using the tetrazolium-based MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] dye reduction assay
(8,14,15) (Promega, Madison, WI, USA). Infected cells were incubated with MTS/PMS solution for 1–4 h at 37°C in a 5% CO2 humidified incubator, and absorbance at 490 nm was measured in a tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Measurement of N7-methylguanine adducts in cells treated with MMS
Two independent techniques were used to measure 7-meG adducts. Infected cells expressing IRES EGFP vector control or HA-MPG were treated with MMS for 1 h starting 24 h after adenoviral infection. MMS-containing medium was removed and replaced with fresh growth medium. Cells were harvested 0, 2, 5 and 25 h after drug treatment, washed three times with PBS and collected by scraping. Cell pellets were frozen at −80°C until DNA isolation and adduct analysis.

N7-meG HPLC-ECD
Quantification of 7-meG in extracted cellular DNA was performed by high-performance liquid chromatography (HPLC) with electrochemical detection (ECD) using a modification of the method published by Park and Ames (16). Between 12 and 55 μg of extracted DNA was adjusted to a final volume of 100 μl with ddH2O. The DNA samples were subjected to neutral thermal hydrolysis at 100°C for 30 min to quantitatively release 7-meG. Depurinated DNA was precipitated by the addition of 10 μl of cold 1 M HCl and removed by centrifugation. To the supernatant, 100 μl of HPLC mobile phase buffer and 9 μl of 1 M NaOH were added. Bases released into the supernatant were separated by reversed phase chromatography (Beckman Ultrasphere C18 column, 25 cm × 4.6 mm, 5 μm particle size) using 50 mM potassium phosphate buffer, pH 5.5/methanol (98:2 (v/v)) as mobile phase at a flow rate of 1 ml/min. The 7-meG adduct was detected by a CoulArray electrochemical detector (ESA, Chelmsford, MA, USA) monitoring oxidation at 500, 600, 700 and 800 mV. The concentration of 7-meG was determined by comparing the peak areas resulting from the ECD of cell samples with those of a series of standards.

Immuino-slot-blot for N7-meG
Experimental samples (1 μg) or a reference standard containing a known amount of N7-meG were denatured in 200 μl TE buffer plus 20 μl 2N NaOH at 37°C for 15 min. This treatment generates 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (imidazole ring-opened 7-meG) from 7-meG. After addition of an equal volume of 2 M ammonium acetate, samples were applied to NC filters using a Minifold II (Schleicher & Schuell). The filters were soaked in 5x SSC (0.75 M NaCl, 75 mM sodium citrate, pH 7.0) for 15 min, dried and baked in a vacuum oven for 2 h at 80°C. Filters were incubated for 2 h at 37°C with blocking buffer [20 mM Tris–HCl (pH 7.5), 0.1 M NaCl, 1 mM EDTA, 0.5% casein and 0.1% deoxycholic acid], followed by a 2 h incubation at 37°C in blocking buffer containing antibody (1:10 000) to imidazole ring-opened 7-methylguanosine (17). The filters were washed extensively in washing buffer [20 mM Tris–HCl (pH 7.5), 0.26 M NaCl, 1 mM EDTA, 0.1% Tween-20] and treated with a labeled polymer (peroxidase-labeled polymer conjugated to goat anti-rabbit and goat anti-mouse immunoglobulins) (Daco) diluted 1:1000 in hybrid buffer. After rinsing the NC membrane, the enzymatic activity on the membrane was visualized by enhanced chemiluminescence reagents (Amersham). The NC filter was exposed to X-ray film, and the developed film was analyzed using a Kodak image analysis system.
The role of MPG glycosylase activity in sensitivity to DNA alkylation damage

In order to determine whether MPG-driven alkylator sensitivity depends on the enzyme’s glycosylase activity, two MPG mutants, Y162A and E125A, were constructed to be selectively inactive in their ability to bind substrate bases or excise them, respectively. Tyrosine 162 plays a role in flipping nucleotides into the enzyme active site, which is required for lesion recognition and DNA binding; glutamic acid 125 then activates a water molecule that is required for hydrolysis of the glycosyl bond (12).

MDA-MB231 breast cancer cells were infected with recombinant adenovirus carrying HA-tagged wild-type, Y162A or E125A MPG or vector control (Figure 1). Western blot analysis at 24 h post-infection showed that these three MPG variants were equivalently overexpressed (data not shown). Cells were treated with the monofunctional alkylating agent MMS or the clinical chemotherapeutic temozolomide 24 h post-infection and incubation was continued for 24 h.

Cell survival was measured using the MTS assay. The results showed that overexpression of wild-type but neither mutant MPG increased the toxicity of MMS and temozolomide relative to the vector control (Figure 1). This proves that the sensitizing effect of MPG overexpression is a result of the enzyme’s glycosylase activity, and further indicates that both binding and excisional components of MPG glycosylase activity are required for the increased alklylation toxicity created by high levels of wild-type MPG.

Lesion specificity of MPG-dependent sensitivity to DNA alkylation damage

Alkylating agents react with nucleophilic centers to form several distinct covalent adducts with DNA bases. The most common sites of alkylation include (in order of prevalence) \(N^1\)-guanine, \(N^2\)-adenine and \(O^6\)-guanine (11). Most simple methylating agents generate predominantly 7-meG adducts and a smaller number of 3-meA and 06-meG adducts.

MPG has a relatively broad substrate specificity and it excises many DNA adducts including 7-meG (11), 3-meA (10), 3-methylguanine (18,19), hypoxanthine (20), 1,N^6-ethenoadenine (21), 3,N^2-ethenoguanine and 8-oxoguanine (22). Because of their prevalence, 7-meG and 3-meA are principal alkylation substrates of MPG. However, the lesions responsible for increased alkylating agent-induced cytotoxicity in MPG-overexpressing cells remain unknown.

In contrast, the mixture of DNA lesions resulting from most alkylating agents, Me-lex, selectively generates 3-meA adducts and was used here to investigate their role in MPG-dependent cytotoxicity. Me-lex is a methyl sulfonate ester tethered to a neutral \(N\)-methylpyrrolecarboxamide-based dipeptide (lex), which confers sequence-selective minor groove DNA binding (23,24). Of the adducts formed by Me-lex, >99% are 3-meA, and a very small fraction are 7-meG (25) or \(O^6\)-meG (26), making Me-lex extremely useful for determining the role of 3-meA lesions in MPG-dependent cytotoxicity. When wild-type cells or cells overexpressing MPG were treated with Me-lex, the results clearly showed that overexpression of MPG had no effect on cell survival (Figure 2), demonstrating that 3-meA is not the lesion involved in MPG-induced alkylator sensitivity.

Quantitative analysis of 7-meG adducts in MMS-treated wild-type and MPG-overexpressing cells

DNA adducts at the highly nucleophilic \(N^7\) position of guanine account for 70–90% of the base modifications generated by monofunctional methylating agents such as MMS (11). Despite its abundance, 7-meG is a relatively innocuous DNA modification, because it does not alter DNA structure, is not mutagenic and does not lead to cell death (27–30). Still, its relative electron deficiency causes 7-meG to be recognized and excised by MPG, even though it presents no threat to the cell. No compounds are currently known to generate 7-meG exclusively in the DNA, but all commonly used methylating agents generate a preponderance of this adduct.

A quantitative analytical approach was developed to establish the possible role of 7-meG adducts in MPG-dependent alkylation-induced cytotoxicity.

Wild-type and MPG-overexpressing cells were treated with sensitizing doses of MMS and cells were then harvested 0, 2, 5
To determine whether methylation at the $N^7$ position of guanine is specifically responsible for MPG-induced alkyla-
tion sensitivity, a number of drugs that append other forms of
damage to guanine were analyzed for their impact on MPG-
overexpressing cell survival. These compounds were ENU,
BCNU, thiotepa ($N^2$, $N^4$, $N^6$-triethylenethiophosphoramide),
4-hydroxy cyclophosphamide (4-HC), MMC and cisplatin. ENU is a
monofunctional alkylating agent that generates ethylation damage at the same $N^7$, O$^6$ and $N^3$A positions as its methyla-
ting counterpart, MNU, which was previously shown to sensitize MPG-overexpressing cells. BCNU is a
monofunctional alkylating agent that has some selectivity for chloroethylating guanine at the O$^6$ position ($11,31$). Thiotepa is a clinical bifunctional alkylating agent that generates $N^7$-guanine- and $N^3$-adenine-targeted aminoethyl adducts ($32$), which can undergo depurination or imidazole
ring-opening to AP sites or 2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FaPyGua) and 4,6-diamino-5-
formamidopyrimidine (FaPyAde) ($33$). 4-HC, the activated
form of the clinical chemotherapeutic cyclophosphamide and
its structural isomer ifosfamide, is a bifunctional alkylating agent with bischloroethyl side chains that
creates $N^7$-guanine-linked interstrand crosslinks in G–X–
C-containing sequences ($34$). Similarly, MMC, an aziridin-
ring-containing DNA cross-linking agent ($35$), forms $N^7$-
guamine-linked interstrand crosslinks. Cisplatin is a square
planar platinum-containing complex with two cis-oriented
chloride leaving groups that preferentially generates intras-
strand DNA crosslinks in dGpdG and dApdG motifs ($34,36$).
MPG recognizes and binds to cisplatin-DNA adducts, but not
does not excise them in vitro ($37$).

Wild-type and MPG-overexpressing cells were treated with
the DNA-damaging agents discussed above and survival curves
were determined 24 or 48 h post-treatment using the MTS
survival assay (see legend to Figure 4 for details). The results
are shown in Figures 4A–F. These data show that overexpres-
sion of MPG in MDA-MB231 cells does not alter the cyto-
toxicity of $N^7$-ethyl-adducted lesions, $N^3$-aminoethyglyuanine
or $N^3$-aminoethyldenamine adducts, O$^6$-chloroethylguanine
adducts, $N^3$-adducted nitrogen mustard monooadducts or
crosslinks, extracyclic guanine monoadducts or crosslinks,
or cisplatin crosslinks. MPG-dependent cytotoxicity in
MDA-MB231 cells appears to be specific to $N^7$-meG adducts
generated by monofunctional methylating agents.

DISCUSSION

We have previously shown that MPG overexpression sensitize-
izes breast cancer cells to the effects of DNA alkylation,
manifested as high levels of baseless and strand-broken DNA
that ultimately lead to considerable increases in cell death ($8$).
The goal of this study was to understand the mechanism by
which overexpression of MPG increases sensitivity to alkyla-
ting agents in MDA-MB231 cancer cells. The data presented
here support the hypothesis that the observed cytotoxicity is
cased by rapid conversion of $7$-meG adducts into toxic repair
intermediates by MPG. 7-meG is not a cytotoxic lesion
and overexpression of MPG, in the absence of exposure to
DNA alkylation damage, is also not cytotoxic; thus, this study
reveals a novel synthetic cytotoxicity uniquely observed in
MPG-overexpressing cells exposed to alkylation damage.

Two MPG mutants deficient in either substrate binding or
excision were used in this study to examine the requirement
for MPG glycosylase activity in generating alkylation sensit-
ity. Overexpression of these two inactive mutants did not in
either case confer the sensitivity seen with wild-type MPG
(Figure 1), demonstrating that both MPG binding and excision
of substrate bases are necessary to confer the dramatic sens-
itivity to alkylation previously seen ($8$). MPG lesion binding
alone is insufficient. The obvious implication is that the pro-
ducts of MPG excisional activity are directly responsible for
increasing toxicity, providing further evidence that unrepaired
AP sites and their downstream strand-broken counterparts lead
to the increased toxicity observed in MPG-overexpressing
cells.

Previous studies have established that the E125A and
Y162A MPG mutants employed here assume a near-native

**Figure 2.** Survival of Me-lex-treated MDA-MB231 cells overexpressing MPG.
MPG-overexpressing cells were treated with Me-lex at the indicated
concentrations and survival was determined as described in Materials and
Methods. Data points are the average of $>10$ independent experiments.
Two-way ANOVA analysis was used to evaluate statistical significance.
There were no statistically significant differences between the vector and
MPG-expressing cells.

and 25 h post-treatment. 7-meG adducts in the DNA were
quantified by two independent methods: HPLC with ECD
and immuno-slot-blotting. The results shown in Figure 3
indicate that a large number of 7-meG adducts accumulate
in wild-type cells following MMS treatment. In contrast,
very few 7-meG adducts are observed at any time point
in cells overexpressing MPG. In fact, the level of 7-meG
in alkylating agent-treated MPG-overexpressing cells was
reduced to at or near baseline at every time point, and in
the more quantitative HPLC assay, levels were below the
limit of detection except immediately following the highest
drug exposure. These data suggest that MPG rapidly and effi-
ciently converts 7-meG adducts into the downstream repair
intermediates previously demonstrated ($8$). This striking, near-
total exchange of benign 7-meG bases for toxic baseless and
strand-broken DNA establishes a role for 7-meG removal in
the sensitizing effect of MPG overexpression.

**MPG-dependent cytotoxicity in the presence of
$N^2$-guanine reactive compounds**

To determine whether methylation at the $N^7$ position of
guanine is specifically responsible for MPG-induced alkyla-
tion sensitivity, a number of drugs that append other forms of
damage to guanine were analyzed for their impact on MPG-
overexpressing cell survival. These compounds were ENU,
BCNU, thiotepa ($N^2$, $N^4$, $N^6$-triethylenethiophosphoramide),
4-hydroxy cyclophosphamide (4-HC), MMC and cisplatin. ENU is a
monofunctional alkylating agent that generates ethylation damage at the same $N^7$, O$^6$ and $N^3$A positions as its methyla-
ting counterpart, MNU, which was previously shown to sensitize MPG-overexpressing cells. BCNU is a
monofunctional alkylating agent that has some selectivity for chloroethylating guanine at the O$^6$ position ($11,31$). Thiotepa is a clinical bifunctional alkylating agent that generates $N^7$-guanine- and $N^3$-adenine-targeted aminoethyl adducts ($32$), which can undergo depurination or imidazole
ring-opening to AP sites or 2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FaPyGua) and 4,6-diamino-5-
formamidopyrimidine (FaPyAde) ($33$). 4-HC, the activated
form of the clinical chemotherapeutic cyclophosphamide and
its structural isomer ifosfamide, is a bifunctional alkylating agent with bischloroethyl side chains that
creates $N^7$-guanine-linked interstrand crosslinks in G–X–
C-containing sequences ($34$). Similarly, MMC, an aziridin-
ring-containing DNA cross-linking agent ($35$), forms $N^7$-
guamine-linked interstrand crosslinks. Cisplatin is a square
planar platinum-containing complex with two cis-oriented
chloride leaving groups that preferentially generates intras-
strand DNA crosslinks in dGpdG and dApdG motifs ($34,36$).
MPG recognizes and binds to cisplatin-DNA adducts, but not
does not excise them in vitro ($37$).
Figure 3. High-performance liquid chromatography (HPLC) analysis of 7-meG lesions per 10^6 nt in the DNA of adenovirally infected MDA-MB231 cells at various time points following treatment with MMS. (A) 7-meG DNA adducts were quantified by HPLC with electrochemical detection in MPG-overexpressing cells or in vector control cells exposed to MMS as indicated. n.d. = below detectable limit. (B) same as (A), except 7-meG was quantified by immuno-slot-blot analysis.
3D structure, despite their aberrant enzymatic function (12). It is therefore unlikely that MPG-induced cytotoxicity results from any other function of the enzyme, including its proposed interaction with the nucleotide excision repair protein hHR23 (38), a function which should be conserved in E125A and Y162A.

MPG has broad specificity for a number of damaged DNA bases. We therefore proceeded to investigate the role of specific alkylated bases in MPG overexpression-induced alkylation sensitivity. The majority of base damage induced by methylation is removed by MPG, including the principal adducts 3-meA and 7-meG (10). Treatment of MPG-overexpressing cells with the minor groove methylation agent Me-lex (23), which selectively introduces >99% 3-meA adducts, was performed in order to discover the contribution of 3-meA to MPG-induced sensitivity. Results

Figure 4. Survival of MPG-overexpressing MDA-MB231 cells exposed to diverse DNA-damaging agents. Wild-type and MPG-overexpressing MDA-MB231 cells were treated with (A) ENU, (B) BCNU, (C) Thiotepa, (D) 4-HC, (E) MMC or (F) Cisplatin. Survival was measured 24 (A and B) or 48 h (C–F) after drug treatment. Two-way ANOVA analysis was used to evaluate statistical significance. There were no statistically significant differences between the vector and MPG-expressing cells for any of the agents shown in this figure.
showed that increased exogenous expression of MPG caused no change in the survival response to Me-lex. These experiments clearly demonstrate that 3-meA removal is not involved in producing sensitivity to alkylation, despite the fact that MPG is able to recognize and excise 3-meA lesions from DNA. One explanation for this result is that the cytotoxicity of 3-meA may be roughly equivalent to the cytotoxicity of downstream intermediates generated during BER of 3-meA. Such an exchange, therefore, even at an increased rate, would not be expected to significantly alter cell survival.

The hypothesis that imbalanced BER has cytotoxic consequences is based on the assumption that downstream repair intermediates can be more cytotoxic than the DNA lesions that trigger repair. Thus, it is relevant to note that 3-meA is intrinsically cytotoxic, because it inhibits DNA polymerases (39,40), but 7-meG, a more abundant DNA lesion, is neither cytotoxic nor mutagenic (29,30). In fact, 7-meG does not appear to have any impact on cell viability. Thus, 7-meG is a likely candidate for the lesion associated with MPG-dependent alkylation agent-induced cytotoxicity because incomplete repair of 7-meG, in contrast to 3-meA, could potentially be more deleterious to the cell than no repair at all.

It is also important to note that MPG removes 3-meA and 7-meG adducts with very different enzyme kinetics. When present at its average endogenous level, MPG excises 7-meG much more slowly than it excises 3-meA (t1/2 = 18 h versus 1 h, respectively). For 3-meA, the rate-limiting step occurs late in the BER pathway, whereas for 7-meG, the rate-limiting step is MPG excision. Furthermore, because 7-meG is abundant and its repair is slow, excision could readily become saturated in wild-type cells with relatively low endogenous MPG (41), and this would not be expected to occur for 3-meA. Increased levels of MPG may therefore selectively increase the excision of 7-meG because of differential enzyme kinetics, supporting the hypothesis that MPG overexpression rapidly converts 7-meG into toxic baseless and strand-broken intermediates and leads to increased cytotoxicity following alkylation agent exposure.

This hypothesis was tested by quantitative HPLC-ECD and immuno-slot-blot analyses of 7-meG adducts in MPG-overexpressing cells (Figure 3). The results show that the removal of 7-meG adducts is much faster and more extensive in MPG-overexpressing cells than in wild-type cells. This confirms that heightened MPG activity is able to increase the normally slow rate of 7-meG excision, shifting the rate-limiting step downstream and leading to the accumulation of toxic repair intermediates. These results strongly implicate 7-meG removal as the mechanism by which MPG overexpression causes sensitivity to alkylation agents.

As demonstrated in this and previous work (8), alkylation agents that generate 7-meG DNA adducts have increased cytotoxicity in cells with heightened levels of MPG. We explored the specificity of this effect using a number of agents that append other forms of damage to guanine. No sensitivity was seen to any of the agents tested, providing further evidence that MPG overexpression exclusively generates sensitivity to compounds that produce 7-meG in the DNA. This further strengthens the hypothesis that rapid conversion of 7-meG adducts into toxic abasic sites and strand breaks is responsible for the increased toxicity of alkylation agents in MPG-overexpressing cells.

CONCLUSION

The results presented here provide insight into BER and the consequences of alkylation damage, and have important implications for clinical chemotherapy.

The rapid removal of 7-meG lesions by increased MPG converts innocuous base changes into toxic repair intermediates that cannot be adequately handled by downstream BER enzymes. The result is a dramatic increase in cell death. This mechanism confirms that uncoordinated handling of even harmless DNA changes can be highly detrimental to the cell, and it underscores the importance of repair pathway management.

These experiments demonstrate that cells risk extreme toxicity to reverse changes to their genetic material and that intervening into these repair mechanisms can alter cell survival. We believe that the results of this study have novel implications for cancer chemotherapy. Because MPG overexpression, which in and of itself is non-toxic, can convert a benign DNA adduct into a highly toxic one by saturating BER, two non-toxic therapies can be used to create cytotoxicity. Of course, the sensitizing effects of MPG overexpression toward 7-meG could be expected to occur in normal as well as cancer cells. However, if independent tumor-targeting strategies, each with distinct tissues of non-specificity, were used for both MPG gene delivery and 7-meG drug delivery, even imprecise targeting could be overcome as the two therapies coincide to produce tumor-specific cell death. The result would be more effective and more specific chemotherapy, leading to decreased peripheral toxicity and improved cancer elimination.

ACKNOWLEDGEMENTS

This work was supported by grants from the National Institutes of Health CA106298, CA094025, ES05865, ES03456 and a P30 DK49218 grant to M.R.K. M.L.R was supported by Department of Defense/Congressionally Directed Mandated Research Program training grant BC011075. J.N. was supported by National Institutes of Health grant R42ES11746, and B.F.P. was supported by National Cancer Institute training grant T32-CA72319. The Riley Children’s Foundation provided additional support. We would also like to heartily thank Dr Rabindra Roy, Georgetown University Medical School, Washington, DC, USA, for the MPG antibody, Dr Robert Bishop for the temozolomide and Dr Rhoderick Elder for the polyclonal antibody against ring-opened N7-meG. We would also like to thank Dr Barry Gold, Eppley Institute for Research in Cancer and Allied Disease and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA for the Me-lex and for reviewing this manuscript. Funding to pay the Open Access publication charges for this article was provided by Riley Children’s Foundation.

Conflict of interest statement. None declared.

REFERENCES

1. Grever, M.R. and Grieshaber, C.K. (2000) Toxicology by organ systems. In Holland, J.F., Frei, E.I., Kufe, D.W., Pollock, R.E., Weichselbaum, R.R. and Bast, R.C. (eds), Holland-Frei Cancer Medicine, 5th edn. B.C. Decker, London, pp. 602–611.
2. Chabner,B.A. and Longo,D.L. (2001) Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd edn. Lippincott Williams & Wilkins, Philadelphia.

3. Krokan,H.E., Nilson,H., Skorpen,F., Otterlei,M. and Slupphaug,G. (2000) Base excision repair of DNA in mammalian cells. FEBS Lett., 476, 73–77.

4. Srivastava,D.K., Berg,B.L., Prasad,R., Molina,J.T., Beard,W.A., Tomkinson,A.E. and Wilson,S.H. (1998) Mammalian abasic site base excision repair. Identification of the reaction sequence and rate-determining steps. J. Biol. Chem., 273, 21203–21209.

5. Lockhart,M.L., Deutsch,J.F., Yamaura,I., Cavalieri,L.F. and Wilkins, Philadelphia. Biotherapy: Principles and Practice, 3rd edn

6. Zhou,W. and Doetsch,P.W. (1993) Effects of abasic sites and DNA single-strand breaks on prokaryotic RNA polymerases. Proc. Natl Acad. Sci. USA, 90, 6601–6605.

7. Caldecott,K.W. (2001) Mammalian DNA single-strand break repair: an X-rayed affair. Bioessays, 23, 447–455.

8. Rinne,M., Caldwell,D. and Kelley,M.R. (2004) Transient adenoviral alkylation with monofunctional alkylating agents. Biochem. Biophys. Res. Commun., 316, 1170–1177.

9. Beranek,D.T. (1990) Distribution of methyl and ethyl adducts following

10. Lau,A.Y., Wyatt,M.D., Glassner,B.J., Samson,L.D. and Ellenberger,T. (1998) 7-Methylguanine adducts in DNA are not at ethyl adducts on the template.

11. Bonanno,K., Wyrzykowski,J., Chong,W., Matijasevic,Z. and Tomkinson,A.E. and Wilson,S.H. (1998) Mammalian abasic site base excision repair. Identification of the reaction sequence and rate-determining steps. J. Biol. Chem., 273, 21203–21209.

12. Park,J.W. and Ames,B.N. (1988) 7-Methylguanine adducts in DNA are not at ethyl adducts on the template.

13. Beranek,D.T. (1990) Distribution of methyl and ethyl adducts following

14. Rinne,M., Caldwell,D. and Kelley,M.R. (2004) Transient adenoviral alkylation with monofunctional alkylating agents. Biochem. Biophys. Res. Commun., 316, 1170–1177.

15. Lockhart,M.L., Deutsch,J.F., Yamaura,I., Cavalieri,L.F. and Wilkins, Philadelphia. Biotherapy: Principles and Practice, 3rd edn

16. Park,J.W. and Ames,B.N. (1988) 7-Methylguanine adducts in DNA are not at ethyl adducts on the template.

17. Beranek,D.T. (1990) Distribution of methyl and ethyl adducts following

18. Rinne,M., Caldwell,D. and Kelley,M.R. (2004) Transient adenoviral alkylation with monofunctional alkylating agents. Biochem. Biophys. Res. Commun., 316, 1170–1177.

19. Beranek,D.T. (1990) Distribution of methyl and ethyl adducts following

20. Saparbaev,M. and Laval,J. (1994) Excision of hypoxanthine from DNA in vitro with electrochemical detection [Erratum (1988) Proc. Natl Acad. Sci. USA, 91, 5873–5877.

21. Dosanjh,M.K., Roy,R., Mitra,S. and Singer,B. (1994) 1,N6-ethenoadenine is preferred over 3-methyladenine as substrate by a cloned human N-methylpurine-DNA glycosylase (3-methyladenine-DNA glycosylase). Biochemistry, 33, 1624–1628.

22. Bessho,T., Roy,R., Yamamoto,K., Kasai,H., Nishimura,S., Tano,K. and Mitra,S. (1993) Repair of 8-hydroxyguanine in DNA by mammalian N-methylpurine-DNA glycosylase. Proc. Natl Acad. Sci. USA, 90, 8901–8904.

23. Zhang,Y., Chen,F.X., Mehta,P. and Gold,B. (1993) Groove- and sequence-selective alkylolation of DNA by sulfonate esters tethered to lexitropsins. Biochemistry, 32, 7954–7965.

24. Shah,D., Kelly,J., Zhang,Y., Dande,P., Martinez,J., Ortiz,G., Fronza,G., Tran,H., Soto,A.M., Marky,L. et al. (2001) Evidence in Escherichia coli that N3-methyladenine lesions induced by a minor groove binding methyl sulphonate ester can be processed by both base and nucleotide excision repair. Biochemistry, 40, 1796–1803.

25. Kelly,J.D., Inga,A., Chen,F.X., Dande,P., Shah,D., Monti,P., Aprile,A., Burns,P.A., Scott,G., Abbondandolo,A. et al. (1999) Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent. J. Biol. Chem., 274, 18327–18334.

26. Encell,L., Shuker,D.E., Foiles,P.G. and Gold,B. (1996) The in vitro methylation of DNA by a minor groove binding methyl sulphonate ester. Chem. Res. Toxicol., 9, 563–567.

27. Kyrtopoulos,S., Anderson,L.M. and Georgiadis,P. (1997) DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer detec. prev., 21, 391–405.

28. Ezaz-Nikpay,K. and Verdine,G.L. (1994) The effects of N7-methylguanine on duplex DNA structure. Chem. Biol., 1, 235–240.

29. Boiteux,S., Huisman,O. and Laval,J. (1984) 3-Methyladenine residues in DNA induce the SOS function sfiA in Escherichia coli. EMBO J., 3, 2569–2573.

30. Lawley,P.D. and Warren,W. (1976) Removal of minor methylation products 7-methyladenine and 3-methyladenine from DNA of Escherichia coli treated with dimethyl sulphate. Chem. Biol. Interact., 12, 211–220.

31. Ludlam,D.B. (1997) The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest., 15, 588–598.

32. Gill,R.D., Cussac,C., Souhami,R.L. and Laval,F. (1996) Increased resistance to N,N,N,N,N,N-tetraethylenetriothiomorphamide (thiotepa) in cells expressing the Escherichia coli formamidopyrimidine-DNA glycosylase. Cancer Res., 56, 3721–3724.

33. Musser,S.M., Pan,S.S. and Callery,P.S. (1989) Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiroycyan and thiotepa. J. Chromatogr., 474, 197–207.

34. Colvin,D.M. (2000) Alkylation agents and platinum antitumor compounds. In Holland,J.F., Frei,E., Kufe,D.W., Pollock,R.E., Weichselbaum,R.R. and Bast,R.C. (eds), Holland-Frei Cancer Medicine, 5th edn.

35. Tomasz,M. and Palom,Y. (1997) The mitomycin bioreductive antitumor agents: cross-linking and alklylation of DNA as the molecular basis of their activity. Pharmacol. Ther., 76, 73–87.

36. Zamble,D.B. and Lippard,S.J. (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci., 20, 435–439.

37. Kartalon,M., Samson,L.D. and Essigmann,J.M. (2000) Cisplatin adducts inhibit 1,6-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase. Biochemistry, 39, 8032–8038.

38. Miao,F., Bouziane,M., Dammann,R., Masutani,C., Hanaoka,F., Pfeifer,G. and O’Connor,T.R. (2000) 3-Methyladenine-DNA glycosylase (MPG protein) interacts with human RAD23 proteins. J. Biol. Chem., 275, 28433–28438.

39. Larsson,K., Sahl,J., Shenkar,R. and Strausa,B. (1985) Methylation-induced blocks to in vitro DNA replication. Mutat. Res., 236, 77–84.

40. Engelward,B.P., Allan,J.M., Dreslin,A.J., Kelly,J.D., Wu,M.M., Gold,B. and Samson,L.D. (1998) A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in mammalian cells. J. Biol. Chem., 273, 5412–5418.

41. Yc.N., Holmquist,G.P. and O’Connor,T.R. (1998) Heterogeneous repair of N-methylpurines at the nucleotide level in normal human cells. J. Mol. Biol., 284, 269–285.